“…There are many examples of such efforts in the recent literature aimed specifically at the identification of repositionable compounds with anti- Candida biofilm inhibitory activity [ 68 ]. While initial studies mostly used C. albicans , most recently these studies have been also extended to C. auris , due to the urgency in identifying new compounds effective against this multi-drug resistant emergent species [ 67 , 69 , 70 ]. A few notable leading repositionable candidates, among others, identified during this work are auranofin, ebselen, alexidine and niclosamide, with ongoing studies aimed at further evaluating their activity both in vitro and in vivo, including in biofilm-relevant models, and advancing their development as antifungals, with emphasis on the treatment of resistant Candida infections, including biofilm-associated candidiasis [ 69 , [71] , [72] , [73] , [74] ].…”